NAMAPA
Latest Content
As more adalimumab biosimilars are poised to enter the market, manufacturers, payers, and patient advocates are preparing to navigate potentially turbulent waters.
Eight JAK inhibitors are approved by the FDA to treat autoimmune, inflammatory, and allergic conditions.
Health care advocates provide a vital service for patients who are managing chronic conditions.
Advertisement
Advertisement
Trending on Drug Topics
1
National Pharmacist Day: Pharmacist, Educator Details Evolution of Scope of Practice
2
Additional Steps in Prescribing Limit RSV Vaccine Access
3
First OTC Pill for Birth Control Significantly Advances Health Equity
4
CPAs Give Community Pharmacists More Active Roles in Health Care
5